BOSTON & ZUG, Switzerland, September 27, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that Vertex has concluded discussions with the U.S. Food and Drug Administration (FDA), and the FDA granted exagamglogene autotemcel (exa-cel) a rolling review for the potential treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). Vertex will submit its biologics licensing application (BLA) for exa-cel for rol
After an all-too-short bounce, the S&P 500 is again in a bear market. The Nasdaq Composite Index has been firmly in bear market territory for weeks. Arguably the smartest place to park $10,000 right now is in the U.S. Treasury's Series I savings bonds.
There are plenty of fierce headwinds in play, but that doesn't mean you should sit on the sidelines.